irl-1620 has been researched along with Stroke* in 2 studies
1 review(s) available for irl-1620 and Stroke
Article | Year |
---|---|
Sovateltide: First Approval.
Sovateltide (Tycamzzi™), a highly selective endothelin-B receptor agonist and synthetic analog of endothelin-1, is being developed by Pharmazz, Inc. as a neural progenitor cell therapeutic agent for the treatment of acute cerebral ischemic stroke (ACIS), hypoxic-ischemic encephalopathy (HIE), spinal cord injuries and Alzheimer's disease. In May 2023, sovateltide was approved in India for the treatment of cerebral ischemic stroke within 24 h of stroke onset. This article summarizes the milestones in the development of sovateltide leading to this first approval for use in patients with ACIS. Topics: Endothelins; Humans; Ischemic Stroke; Peptide Fragments; Stroke | 2023 |
1 other study(ies) available for irl-1620 and Stroke
Article | Year |
---|---|
Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke.
The development of effective drugs for stroke is urgently required as it is the 2nd largest killer in the world and its incidence is likely to increase in the future. We have demonstrated cerebral endothelin B receptors (ETBR) as a potential target to treat acute cerebral ischemic stroke. However, the mechanism of ETBR mediated neural regeneration and repair remains elusive. In this study, a permanent middle cerebral artery occluded (MCAO) rat model was used. Sovateltide (an ETBR agonist) injected intravenously showed better survival and neurological and motor function improvement than control. Higher neuronal progenitor cells (NPCs) differentiation along with better mitochondrial morphology and biogenesis in the brain of sovateltide rats were noted. Exposure of cultured NPCs to hypoxia and sovateltide also showed higher NPC differentiation and maturation. This study shows a novel role of ETBR in NPCs and mitochondrial fate determination in cerebral ischemia, and in improving neurological deficit after stroke. Topics: Administration, Intravenous; Animals; Antigens, Nuclear; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Cell Hypoxia; Disease Models, Animal; Dynamins; Endothelins; GTP Phosphohydrolases; Infarction, Middle Cerebral Artery; Male; Mitochondria; Mitochondrial Dynamics; Mitochondrial Proteins; Nerve Tissue Proteins; Neural Stem Cells; Peptide Fragments; Rats; Stroke | 2020 |